-
Sell-Side Likes Peloton's Winning First Quarter As Public Company
Wednesday, November 6, 2019 - 1:55pm | 400Peloton Interactive Inc (NASDAQ: PTON) saw stronger results than expected in nearly every metric in the connected fitness bike provider's first quarter as a public company, keeping sell-side analysts along for the ride. The Analysts JMP's Ronald Josey reiterated a Market Outperform rating...
-
What The Street Thinks Of Under Armour's Q3 Beat As Accounting Investigation Continues
Wednesday, November 6, 2019 - 12:01pm | 726Under Armour Inc (NASDAQ: UAA) shares are recovering slightly after suffering a massive drop Monday after the company confirmed it's facing an investigation by the Securities and Exchange Commission and Justice Department into its accounting practices. On Monday, the apparel company reported a...
-
'Significant Risk': Under Armour Analysts On Federal Investigation Of Apparel Company's Accounting
Tuesday, November 5, 2019 - 3:48pm | 624Under Armour Inc (NASDAQ: UAA) reported a solid third-quarter earnings beat Monday, but was any upside was drowned out by the news that the company's accounting is the subject of a probe by the SEC and Justice Department. The sportswear company is being investigated for its revenue-recognition...
-
EA's Strong Quarter Overshadowed By 'Battlefield' Pushout
Wednesday, October 30, 2019 - 11:10am | 486Electronic Arts Inc. (NASDAQ: EA) turned in an unexpectedly strong second quarter with revenue and earnings beating expectations. But analysts' enthusiasm was limited by the company's unexpected decision to push the next title in its "Battlefield" franchise out a year to 2022,...
-
Texas Roadhouse Serves Up Juicy Quarter, But Street Isn't Buying The Sizzle
Tuesday, October 29, 2019 - 1:35pm | 575Texas Roadhouse Inc (NASDAQ: TXRH) reported third-quarter results, which was mostly cheered by Street analysts but sparked a debate if investors should buy the stock. Q3 Sizzles Texas Roadhouse's quarter report is highlighted by a "solid" comps beat of 4.4% versus 4.3%, a "...
-
Gilead Falls On Uninspiring Q3 Print: 3 Analyst Takes
Friday, October 25, 2019 - 12:41pm | 824Gilead Sciences, Inc. (NASDAQ: GILD) reported after the market close Thursday with results that left investors uninspired. The Analysts Morgan Stanley analyst Matthew Harrison maintained an Equal-weight rating on Gilead with a $75 price target. Baird analyst Brian Skorney maintained...
-
Baird Upgrades FMC On Prospects Of Above-Market Revenue Growth For Several Years
Wednesday, October 16, 2019 - 1:00pm | 352FMC Corp (NYSE: FMC) seems well-positioned to generate top-line and adjusted EBITDA growth in 2020 and beyond, driven by new product launches, share gains in key markets and operating leverage, according to Baird. The Analyst Baird’s Ben Kallo upgraded FMC from Neutral to Outperform, raising...
-
Despite Lackluster Quarter, Sell-Side Says Domino's Will Eventually Beat Back New Third-Party Delivery Competition
Wednesday, October 9, 2019 - 12:19pm | 627Domino’s Pizza, Inc. (NYSE: DPZ) was in the delivery business before delivery was so cool, and it will withstand the current onslaught of new food delivery companies, analysts said as they kept bullish ratings intact despite mixed third-quarter results. The Analysts Wedbush analyst Nick...
-
Sell-Side: Wells Fargo's New CEO A Good Hire, But Don't Look For A Quick Fix
Monday, September 30, 2019 - 1:45pm | 681Wells Fargo & Co (NYSE: WFC)’s new CEO should bring some needed stability as the bank tries to get out from under regulatory restrictions, but a return to growth won’t happen overnight, sell-side analysts said from the sidelines Monday. The bank announced Friday that Charlie...
-
Biotech Stock On The Radar: Aimmune Awaits Adcom Test
Tuesday, September 10, 2019 - 4:37pm | 1710Aimmune Therapeutics Inc (NASDAQ: AIMT) shares have been on an extended downtrend since the start of 2018. This thinly traded, small-cap biotech is on the radar ahead of a key FDA panel meeting scheduled for Friday, Sept. 13. A briefing document posted on the FDA’s website Wednesday...
-
Axovant Analyst Turns Bullish Ahead Of Q4 Gene Therapy Data Readouts
Monday, August 12, 2019 - 5:48pm | 517Gene therapy is an emerging therapeutic area, and Axovant Gene Therapies Ltd (NASDAQ: AXGT) is an attractive play on the sector, according to Baird. The Analyst Brian Skorney upgraded Axovant from Neutral to Outperform and lowered the price target from $16 to $13. The Thesis Axovant...
-
Walmart Analyst Bullish Ahead Of Quarterly Report, Says Tariff Impact 'Seems Manageable'
Monday, August 12, 2019 - 3:25pm | 400Walmart Inc (NYSE: WMT) is likely to show continued strength in multiple financial metrics when it reports second quarter earnings Thursday, Aug. 15, according to Baird. The Analyst Peter Benedict maintained an Outperform rating on Walmart with an unchanged $115 price target. The Thesis...
-
Baird Sees Entry Point In Target Ahead Of Q2 Print
Monday, August 12, 2019 - 1:37pm | 428Target Corporation (NYSE: TGT) shares are higher by more than 25% since the start of 2019, and the stock still offers investors a compelling entry point ahead of the second-quarter print Aug. 21, according to Baird. The Analyst Peter Benedict maintained an Outperform rating on Target with an...
-
The Sell-Side Digs Into Twilio Earnings
Thursday, August 1, 2019 - 2:31pm | 525Twilio Inc (NYSE: TWLO) reported in-line second-quarter EPS and revenue above analyst expectations. The company also issued third-quarter guidance above consensus estimates and said it reached a $1 billion annual revenue run rate in the second quarter for the first time. Twilio is up 56% year to...
-
'Concerning Trend': Wall Street Weighs In On Tesla's Q2 Earnings
Thursday, July 25, 2019 - 11:52am | 704Tesla Inc (NASDAQ: TSLA) shares plummeted on Thursday after the company reported a much larger-than-expected loss in the second quarter and fell short of consensus revenue estimates as well. Tesla reiterated its full-year vehicle delivery guidance of between 360,000 and 400,000 units and once again...